Zafgen

Cambridge, United States Founded: 2005 • Age: 21 yrs Listed
Therapeutics for obesity are developed by targeting fat tissue.

About Zafgen

Zafgen is a publicly listed company based in Cambridge (United States) founded in 2005. Therapeutics for obesity are developed by targeting fat tissue. Zafgen has raised $127.76 million across 6 funding rounds from investors including RA Capital, Atlas Venture and Oxford. Its chief executive, as recorded, is Thomas Hughes. Zafgen offers products and services including Power Shape, Visadore, Acust Oil PRO, Psoryden, and Biotrim Maximum. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Alnylam, Ultragenyx and BioMarin Pharmaceutical; 3 of its 3 listed competitors have raised funding.

Company details

Zafgen was founded in 2005 and is headquartered in Cambridge, United States. The company operates in the biotechnology sector, focusing on the development of therapeutics for obesity treatment. These therapies aim to reduce fat tissue directly, promoting a sustained lean state. The lead candidate, Beloranib, is in phase 3 trials for Prader-Willi syndrome and is evaluated as an alternative to bariatric surgery.

  • Headquarters Cambridge, United States
  • Stage Public
  • Sectors
    Healthcare
  • Website zafgen.com
  • Social LinkedIn X
Operational Areas
Key Metrics
  • Total Equity Funding
    $127.76M (USD)

    in 6 rounds

  • Latest Funding Round
    $20M (USD), Debt – Conventional

    Apr 2014

  • Investors
    RA Capital

    & 7 more

Products & Services of Zafgen

Zafgen offers a comprehensive portfolio of products and services, including Power Shape, Visadore, Acust Oil PRO, Psoryden, and Biotrim Maximum.

Power Shape
Weight Loss

Capsules aimed at supporting weight loss through dietary aid

Visadore
Beauty

Creme for preventing skin aging and maintaining elasticity

Acust Oil PRO
Health

Tropfen for managing tinnitus and related ear issues

Psoryden
Health

Creme targeted at treating psoriasis symptoms

Biotrim Maximum
Weight Loss

Tablets for aiding balanced diet and weight management

Betasulin
Health

Kapseln for diabetes management and health support

Bullrun Ero
Health

Kapseln designed to enhance sexual potency and stamina

NightBeast
Health

Creme for improving sleep and overall well-being

Keton Aktiv
Weight Loss

Kapseln for supporting calorie deficit and fat loss

ProstAktiv
Health

Kapseln for addressing prostate-related health concerns

Funding Insights of Zafgen

Zafgen has successfully raised a total of $127.76M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $20 million completed in April 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $127.76M
  • Total Rounds 6
  • Last Round Debt – Conventional β€” $20M
  • First Round $28M

    (Mar 2010)

  • Investors Count 8

All 6 funding rounds of Zafgen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2014$20MDebt – Conventional––
Dec 2013$45MSeries E––
Dec 2012$21.76MSeries D–Alta Partners
Aug 2012$3MDebt – Conventional––
–
Jul 2011$33MSeries C–Atlas Venture, Third Rock Ventures
–
Mar 2010$28MSeries B–Third Rock Ventures
Valuation history

8 investors in total: 8 institutional.

Investors in Zafgen

Zafgen has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, Atlas Venture and Oxford.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on multiple sectors
brooksidecapital.comSan Francisco, United States
Venture capital firm focused on tech sectors
venrock.comPalo Alto, United States
Venture capital firm focused on healthcare companies
altapartners.comJackson, United States
Venture capital firm investing in life science and biotechnology sectors
1980atlasventure.comCambridge, United States
Venture capital funding is provided to early-stage life science companies.
thirdrockventures.comBoston, United States
oxfordna.org
Offers customized loans and financing to small and mid-size companies across industries.
2004midcapcredit.comWest Hartford, United States
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
2004racap.comBoston, United States
Premium access

Investor details for Zafgen

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Zafgen

10 people are tracked at Zafgen (3 in leadership, 7 in board & advisors).

NameRoleGroup
Thomas Hughes
CEOLeadership
Jeffrey S. Hatfield
CEOLeadership
Brian P. Mcveigh
Chief Business OfficerLeadership
Thomas O. Daniel
DirectorBoard & advisors
Peter Barrett
ChairmanBoard & advisors
Wendy Everett
DirectorBoard & advisors
Frank E. Thomas
DirectorBoard & advisors
Robert J. Perez
DirectorBoard & advisors
C. Geoffrey Mcdonough
DirectorBoard & advisors
John Lamattina
DirectorBoard & advisors
Premium access

Complete people profiles for Zafgen

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Zafgen

4 dated milestones of Zafgen across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Zafgen is founded.
  2. Funding First funding round of $28.0M.
  3. Funding Latest funding round, Debt – Conventional, of $20.0M.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Zafgen

Zafgen has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and BioMarin Pharmaceutical.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
ultragenyx.com2010Novato, United States$135.1M837
Therapeutics for rare and ultra-rare metabolic diseases are developed.
biomarin.com1997San Rafael, United States$37.5M2,124
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
Premium access

Detailed competitors of Zafgen

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Zafgen

Websites that share an audience with Zafgen (zafgen.com).

Similar websites

Websites whose visitors overlap most with Zafgen. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
momentapharma.com
100%
#11,284,544View details
orexigen.com
94%
View details
fiercebiotech.com
89%
858.3K#81,022View details
dddmag.com
dddmag.com
62%
–
domuk.org
domuk.org
58%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 6 similar websites and full traffic analytics for Zafgen

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Rare Diseases

3 companies that operate in the same segment as Zafgen (Rare Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Gene therapies for rare diseases including retinal dystrophies are developed.
2013Philadelphia, Pennsylvania, United StatesUSD 82.8 MUSD 64.73 M822
Therapeutics for genetic diseases are developed through targeted interventions.
2015Palo Alto, California, United StatesUSD 434.2 MUSD 502.08 M730
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Zafgen

Premium access

Complete news archive for Zafgen

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Zafgen

Zafgen was founded in 2005 and raised its 1st funding round 5 years after it was founded.

Zafgen is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Thomas Hughes is the CEO of Zafgen, as recorded in our data.

Zafgen is a funded company, having raised a total of $127.76M across 6 funding rounds to date. The company's 1st funding round was a Series B of $28M, raised on Mar 2010.

Zafgen was founded in 2005 and is headquartered in Cambridge, United States. The company operates in the biotechnology sector, focusing on the development of therapeutics for obesity treatment. These therapies aim to reduce fat tissue directly, promoting a sustained lean state. The lead candidate, Beloranib, is in phase 3 trials for Prader-Willi syndrome and is evaluated as an alternative to bariatric surgery.

Zafgen's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.

Zafgen offers Power Shape, Visadore, Acust Oil PRO, Psoryden, and 6 more products and services.

Zafgen has 8 investors. Key investors include RA Capital, Atlas Venture, Oxford, Midcapcredit, and Brookside Capital.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available